Integra LifeSciences Holdings (IART) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
Total Revenue Chart for Integra LifeSciences Holdings
Integra LifeSciences Holdings (IART) revenue for FY2025 was USD 1.6B, a 1.5% change from FY2024. Integra LifeSciences Holdings's revenue grew from USD 10.2M in 1995 to USD 1.6B in 2025 (15931.8% over 30 years). Earnings per share grew from USD 0.46 in 2001 to USD 2.16 in 2022 (373.5%). Revenue compound annual growth rate: 5-year CAGR of 3.6%, 10-year CAGR of 6.4%, 20-year CAGR of 9.3%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $926.27M
- Implied Share Price
- $11.91
- Enterprise Value
- $3.02B
- Revenue (TTM)
- $1.66B
- EBITDA
- $311.51M
- Profit Margin
- 0.79%
- Trailing P/E
- 70.06
- Forward P/E
- 6.00
- Price/Book (MRQ)
- 1.19
- Price/Sales (TTM)
- 0.56
- EV/EBITDA
- 12.32
- EV/Revenue
- 1.83
- Dividend Yield
- —
- Book Value
- $13.41
- Free Cash Flow (FY2025)
- -$45.25M
- Free Cash Flow Yield
- -4.89%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.